Do you know what…?
How did doctors tailor a gene-editing medicine to just one baby?
AI-generated image, not a photograph. This edition's article, audio and test are AI-generated and published automatically without prior human review. Sources · Editorial & AI Policy
Listen to today’s article
In 2025, researchers tailored an experimental treatment to an infant's particular genetic mutation, rather than choosing a medicine for a disease category. The child had carbamoyl-phosphate synthetase 1 deficiency, known as CPS1 deficiency. His treatment used CRISPR base editing: a technique designed to change a targeted DNA letter rather than replace an entire gene. According to the US National Institutes of Health (NIH), this was the first known occasion on which someone received a gene-editing medicine developed specifically for them. The organising principle was the patient's mutation, not simply the diagnostic label.
The development speed was just as striking: NIH put the interval from diagnosis to the start of treatment at six months. This was not simply a prescription for an existing drug, but a mutation-specific developed during infancy. Lipid nanoparticles—tiny fat-based carriers—packaged the editing molecules and delivered them to the liver, where the treatment aimed to correct the mutation. Designing the editor and transporting it are distinct challenges: a molecular tool cannot work unless it reaches suitable cells. NIH reported an early positive response in May 2025, but that observation did not establish a cure.
The enduring significance of this 2025 case is that it could for further personalised treatments, not that it has settled their safety or effectiveness. NIH's Somatic Cell Genome Editing programme supported the work; its separate TARGETED delivery challenge illustrates why getting editors to the right cells remains a research priority. An individual experimental treatment is not a randomised trial, and an early response cannot establish benefit or lifelong safety. Broader use remains a prospect: the practical question is whether researchers can reproduce the approach for other mutations without assuming that the same timetable or results will follow.